Analysts Set TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Target Price at $11.79

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned an average recommendation of “Buy” from the nine analysts that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $11.79.

A number of research firms recently weighed in on TLSI. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Roth Mkm reissued a “buy” rating and set a $11.00 price objective on shares of TriSalus Life Sciences in a report on Friday, January 24th. Northland Securities started coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They issued an “outperform” rating and a $12.50 target price for the company. Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Finally, Canaccord Genuity Group dropped their price objective on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 15th.

Insider Activity

In other news, CEO Mary T. Szela acquired 4,826 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was bought at an average price of $5.42 per share, with a total value of $26,156.92. Following the completion of the acquisition, the chief executive officer now owns 429,503 shares in the company, valued at approximately $2,327,906.26. This represents a 1.14 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Equity Ab Frankenius bought 62,972 shares of TriSalus Life Sciences stock in a transaction dated Tuesday, December 17th. The stock was acquired at an average cost of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the acquisition, the insider now directly owns 6,230,748 shares in the company, valued at $24,736,069.56. This represents a 1.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have bought 124,868 shares of company stock worth $575,843. Corporate insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of TLSI. Geode Capital Management LLC grew its holdings in shares of TriSalus Life Sciences by 45.4% during the third quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after purchasing an additional 62,542 shares during the last quarter. MSD Partners L.P. acquired a new position in TriSalus Life Sciences during the 3rd quarter worth about $184,000. Vestcor Inc bought a new stake in TriSalus Life Sciences during the 3rd quarter worth about $108,000. Virtu Financial LLC bought a new stake in TriSalus Life Sciences during the 3rd quarter worth about $92,000. Finally, Walleye Capital LLC acquired a new stake in TriSalus Life Sciences in the 3rd quarter valued at about $66,000. 2.58% of the stock is owned by institutional investors and hedge funds.

TriSalus Life Sciences Price Performance

NASDAQ TLSI opened at $5.57 on Monday. The company’s fifty day moving average is $4.70 and its two-hundred day moving average is $4.74. The firm has a market capitalization of $169.85 million, a price-to-earnings ratio of -2.24 and a beta of 0.51. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.